Adoptive cell therapy (ACT) is a category of immunotherapy currently being studied in clinical trials to treat metastatic breast cancer. Types of ACT immunotherapy include CAR-T therapy and TIL therapy.
Receiving any type of ACT immunotherapy is a multi-step process. One process is lymphodepletion — also called lymph-depleting or preconditioning. Typically, lymphodepletion involves the patient receiving a short course of chemotherapy to kill their T cells (a part of their immune system) before they receive the ACT immunotherapy.
Follow the links below to learn why lymphodepletion is used, the pros and cons of lymphodepletion, research questions about best practices in lymphodepletion, and MBC clinical trials studying ACT immunotherapies.
What is Lymphodepletion?
- Multiple Myeloma Hub: Lymphodepletion Optimization for CAR T-cell therapy
- Time to Talk Immuno-Oncology: What is CAR T-Cell Therapy
- Cytiva: Tumor-Infiltrating Lymphocytes as Cell Therapies
Side Effects of Lymph-Depleting Chemotherapy
Research Into Preconditioning Best Practices
- Expert Opinion on Biological Therapy: Lymphodepletion Strategies to Potentiate Adoptive T-cell immunotherapy – What are We Doing; Where are we Going?
- Journal for ImmunoTherapy of Cancer: Comparison of Non-Myeloablative Lymphodepleting Preconditioning Regimens in Patients Undergoing Adoptive T Cell Therapy